A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

NCT01326871 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Transitional Cell Carcinoma of Bladder
Urethra Cancer
Ureter Cancer
Malignant Tumor of Renal Pelvis

Interventions

DRUG: Cisplatin
DRUG: Gemcitabine
BIOLOGICAL: ALT-801

Sponsor

Altor BioScience

Collaborators

[object Object]